Gastroesophageal reflux disease

Journal of Family Practice

Volumn 52, Issue 3, 2003, Pages 240-247

  Howden, Colin W ^a   Chey, William D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIET; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; REVIEW; SENSITIVITY AND SPECIFICITY;

CLINICAL TRIALS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PRACTICE GUIDELINES; RISK REDUCTION BEHAVIOR;

EID: 0037337014     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199:18-21.
2. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104:252-8.
3. Peterson, WL. GERD: Evidence-based therapeutic strategies. Bethesda, Md: American Gastroenterological Association; 2002.
4. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001; 322:344-7.
5. Harding SM. Nocturnal asthma: role of gastroesophageal reflux. Chronobiol Int 1999; 16:641-2.
6. Kjellen G, Wranne B. The prevalence of asymptomatic gastro-oesophageal relfux in adult patients with asthma. Eur J Respir Dis 1984; 65:233.
7. Schnatz PF, Castell JA, Castell DO. Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. Am J Gastroenterol 1996; 91:1715-8.
8. Sontag SJ, Schnell TG, Miller TQ, Khandelwal S, O'Connell S, Chejfec G, et al. Prevalence of oesophagitis in asthmatics. Gut 1992; 33:872-6.
9. Schofield PM, Bennett DH, Whorwell PJ, Brooks NH, Bray CL, Ward C, et al. Exertional gastro-oesophageal reflux: a mechanism for symptoms in patients with angina pectoris and normal coronary angiograms. Br Med J (Clin Res Ed) 1987; 294:1459-61.
10. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90:576-83.
11. Goyal RK. Diseases of the esophagus. In: Braunwald E, ed. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill; 2001:1642-9.
12. Schenk BE, Kulpers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92:1997-2000.
13. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001;(4):CD002095.
14. Brun J, Sorngard H. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care. Fam Pract 2000; 17:401-4.
15. Lundell L. Anti-reflux surgery in the laparoscopic era. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:793-810.
16. Chen MY, Ott DJ, Sinclair JW, Wu WC, Gelfand DW. Gastroesophageal reflux disease: correlation of esophageal pH testing and radiographic findings. Radiology 1992; 185:483-6.
17. The role of endoscopy in the management of GERD: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1999; 49:834-5.
18. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94:1434-42.
19. Beck IT, Champion MC, Lemire S, Thomson AB, Anvari M, Armstrong D, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997; 11(suppl B):7B-20B.
20. Chey WD, Inadomi JM, Booher AK, Fendrick AM. Primary care physicians' perceptions and practices of the management of GERD: results of a national survey. Abstract presented at: DDW 2003; May 17-23, 2003; Orlando, Fla.
21. Fennerty MB, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas PJ, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines. Arch Intern Med 1996; 156:477-84.
22. Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion 1977; 15:104-9.
23. Harvey RF, Gordon PC, Hadley N, Long DE, Gill TR, Macpherson RI, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet 1987; 2:1200-3.
24. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci 1983; 28:559-63.
25. Grove O, Bekker C, Jeppe-Hansen MG, Karstoft E, Sanchez G, Axelsson CK, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol 1985; 20:457-61.
26. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989; 24:401-6.
27. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40:52-62.
28. Barnardo DE, Lancaster-Smith M, Strickland ID, Wright JT. A double-blind controlled trial of 'Gaviscon' in patients with symptomatic gastrooesophageal reflux. Curr Med Res Opin 1975; 3:388-91.
29. Beeley M, Warner JO. Medical treatment of symptomatic hiatus hernia with low-density compounds. Curr Med Res Opin 1972; 1:63-9.
30. Chevrel B. A comparative crossover study on the treatment of heartburn and epigastric pain: liquid Gaviscon and a magnesium-aluminium antacid gel. J Int Med Res 1980; 8:300-2.
31. Laitinen S, Stahlberg M, Kairaluoma MI, Kiviniemi H, Paakkonen M, Lahtinen J, et al. Sucralfate and alginate/antacid in reflux esophagitis. Scand J Gastroenterol 1985; 20:229-32.
32. Lanza FL, Smith V, Page-Castell JA, Castell DO. Effectiveness of foaming antacid in relieving induced heartburn. South Med J 1986; 79:327-30.
33. McHardy G. A multicentric, randomized clinical trial of Gaviscon in reflux esophagitis. South Med J 1978; 71(suppl 1):16-21.
34. Stanciu C, Bennett JR. Alginate-antacid in the reduction of gastrooesophageal reflux. Lancet 1974; 1:109-11.
35. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001; 15:1571-7.
36. Spiegel JE, Thoden WR, Pappas K, Fratarcangelo P, Furey SA. A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heart-burn. Arch Intern Med 1997; 157:1594-9.
37. Pappa KA, Buaron K, Payne JE, Sirgo MA, Giefer EE. An evaluation of increasing doses of ranitidine for treatment of heartburn. Aliment Pharmacol Ther 1999; 13:475-81.
38. Pappa KA, Gooch WM, Buaron K, Payne JE, Giefer EE, Sirgo MA, et al. Low-dose ranitidine for the relief of heartburn. Aliment Pharmacol Ther 1999; 13:459-65.
39. Pappa KA, Williams BO, Payne JE, Buaron KS, Mussari KL, Ciociola AA. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther 1999; 13:467-73.
40. Ciociola AA, Pappa KA, Sirgo MA. Nonprescription doses of ranitidine are effective in the relief of episodic heart-burn. Am J Ther 2001; 8:399-408.
41. Gottlieb S, Decktor DL, Eckert JM, Simon TJ, Stauffer L, Ciccone PE. Efficacy and tolerability of famotidine in preventing heartburn and related symptoms of upper gastrointestinal discomfort. Am J Ther 1995; 2:314-9.
42. Simon TJ, Berlin RG, Gardner AH, Stauffer LA, Gould AL, Getson AJ. Self-directed treatment of intermittent heartburn: a randomized, multicenter, double-blind, placebo-controlled evaluation of antacid and low doses of an H(2)-receptor antagonist (famotidine). Am J Ther 1995; 2:304-13.
43. Galmiche JP, Shi G, Simon B, Casset-Semanza F, Slama A. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther 1998; 12:909-17.
44. Qvigstad G, Arnestad JS, Brenna E, Waldum HL. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol 1998; 33:1244-8.
45. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997; 92(suppl):17S-21S.
46. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15:227-31.
47. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15:1729-36.
48. Dupas JL, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol 2001; 25:245-50.
49. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97:575-83.
50. Howden CW, Ballard ED, Robison W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22:99-109.
51. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45:845-53.
52. Carling L, Axelsson CK, Forssell H, Stubberod A, Kraglund K, Bonnevie O, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998; 12:985-90.
53. Chey WD, Inadmoni JM, Boojer AK, Fendrick AM. What do primary care physicians think about Barrett's esophagus, the relationship between GERD and H. pylori, and treatment of nocturnal heartburn? Abstract presented at: DDW 2003; May 17-23, 2003; Orlando, Fla.
54. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-95.
55. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285:2331-8.
56. Katz PO. Gastroesophageal reflux disease: new treatments. Rev Gastroenterol Disord 2002; 2:66-74.